Sesamin, a lignan of sesame, down-regulates cyclin D1 protein expression in human tumor cells

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1447-1453

  Yokota, Tomoya ^a   Matsuzaki, Youichirou ^a   Koyama, Makoto ^a   Hitomi, Toshiaki ^a   Kawanaka, Mayumi ^a   Enoki konishi, Masako ^a   Okuyama, Yusuke ^a,d   Takayasu, Junko ^a   Nishino, Hoyoku ^a   Nishikawa, Akiyoshi ^b   Osawa, Toshihiko ^c   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; LIGNAN; PROTEASOME; PROTEASOME INHIBITOR; RETINOBLASTOMA PROTEIN; SESAMIN; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; KIDNEY CELL; LUNG CANCER; MELANOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SESAME;

BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DIOXOLES; DOWN-REGULATION; G1 PHASE; GROWTH INHIBITORS; HUMANS; LIGNANS; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RETINOBLASTOMA PROTEIN; SESAME OIL;

EID: 34547817740     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00560.x     Document Type: Article

References (35)

1. Noguchi T, Ikeda K, Sasaki Y et al. Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Hypertens Res 2001; 24: 735-42.
2. Ide T, Ashakumary L, Takahashi Y, Kushiro M, Fukuda N, Sugano M. Sesamin, a sesame lignan, decreases fatty acid synthesis in rat liver accompanying the down-regulation of sterol regulatory element binding protein-1. Biochim Biophys Acta 2001; 1534: 1-13.
3. Umeda-Sawada R, Ogawa M, Nakamura M, Igarashi O. Effect of sesamin on mitochondrial and peroxisomal beta-oxidation of arachidonic and eicosapentaenoic acids in rat liver. Lipids 2001; 36: 483-9.
4. Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, Matsumura Y. Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol Pharm Bull 2002; 25: 1247-9.
5. Nakano D, Itoh C, Ishii F et al. Effects of sesamin on aortic oxidative stress and endothelial dysfunction in deoxycorticosterone acetate-salt hypertensive rats. Biol Pharm Bull 2003; 26: 1701-5.
6. Nakai M, Harada M, Nakahara K et al. Novel antioxidative metabolites in rat liver with ingested sesamin. J Agric Food Chem 2003; 51: 1666-70.
7. Hirose N, Doi F, Ueki T et al. Suppressive effect of sesamin against 7,12-dimethylbenz[a]-anthracene induced rat mammary carcinogenesis. Anticancer Res 1992; 12: 1259-65.
8. Hibasami H, Fujikawa T, Takeda H et al. Induction of apoptosis by Acanthopanax senticosus HARMS and its component, sesamin in human stomach cancer KATO III cells. Oncol Rep 2000; 7: 1213-16.
9. Miyahara Y, Komiya T, Katsuzaki H et al. Sesamin and episesamin induce apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med 2000; 6: 43-6.
10. Ju Y, Still CC, Sacalis JN, Li J, Ho CT. Cytotoxic coumarins and lignans from extracts of the northern prickly ash (Zanthoxylum americanum). Phytother Res 2001; 15: 441-3.
11. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-65.
12. Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D Cyclins. Cell 1993; 73: 499-511.
13. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
14. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
15. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-7.
16. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin d -dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15: 2672-81.
17. Zariwala M, Xiong Y. Lack of mutation in the cyclin-dependent kinase inhibitor, p19 INK4d, in tumor-derived cell lines and primary tumors. Oncogene 1996; 13: 2033-8.
18. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11: 957-72.
19. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-511.
20. Lee DH, Goldberg AL. Proteasome inhibitors: Valuable new tools for cell biologists. Trends Cell Biol 1998; 8: 397-403.
21. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism. Proc Natl Acad Sci USA 1997; 94: 12 070-4.
22. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21: 8852-61.
23. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
24. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27 (Kip1) ubiquitination and degradation is regulated by the SCF (Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661-4.
25. Lin DI, Barbash O, Kumar KG et al. Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF (FBX4-alphaB crystallin) complex. Mol Cell 2006; 24: 355-66.
26. Matsumura Y, Kita S, Morimoto S et al. Antihypertensive effect of sesamin. I. Protection against deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy. Biol Pharm Bull 1995; 18: 1016-19.
27. Matsumura Y, Kita S, Tanida Y et al. Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats. Biol Pharm Bull 1998; 21: 469-73.
28. Kita S, Matsumura Y, Morimoto S et al. Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Biol Pharm Bull 1995; 18: 1283-5.
29. Akimoto K, Asami S, Shimizu S, Sugano M, Yamada H. Antioxidant activity of sesamin on nadph-dependent peroxidation in liver microsomes. In: Kumpulainen JT, Salonen JT, eds. Natural Antioxidants and Food Quality in Atherosclerosis and Cancer Prevention. London: The Royal Society of Chemistry, 1996: 241-6.
30. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226-31.
31. Hosokawa Y, Arnold A. Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele-specific expression. Genes Chromosomes Cancer 1998; 22: 66-71.
32. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-71.
33. Sakai T. Molecular cancer epidemiology-the present status and future possibilities. Jpn J Hygiene 1996; 50: 1036-46.
34. Sowa Y, Sakai T. Butyrate as a model for 'gene-regulating chemoprevention and chemotherapy'. Biofactors 2000; 12: 283-7.
35. Matsuzaki Y, Sowa Y, Hirose T, Yokota T, Sakai T. Histone deacetylase inhibitors-promising agents for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer. Environ Health Prev Med 2003; 8: 157-60.